conference reports
Identification of a new anti-invasive low molecular weight compound
Tuesday, 23 June 2009- E-cadherin (CDH1) is an essential cell adhesion molecule that is downregulated during progression of, amongst others, bladder and prostate cancer. Impaired E-cadherin function often results from...
By Joel Vega
Experts discuss PCa issues in Amsterdam meeting
Monday, 22 June 2009- Updates on current research work regarding genetic variants and how it affects the risk of prostate cancer were provided by leading experts at the Prostate Cancer Transational Research in Europe meeting...
By Lindy Brouwer
Imaging of PCa and metastasis using antibodies targeting prostate kallikreins
Monday, 22 June 2009- Early diagnosis and the ability to treat aggressive/metastasised prostate cancer (PCa) are essential in decreasing the mortality rate. Prostate specific antigen (PSA) is the biomarker most used in PCa...
Edited by: Joel Vega
Increased expression of androgen receptor in metastatic PCa
Monday, 22 June 2009- Androgen receptor (AR) signalling remains active in castration-resistant prostate cancer (CRPC) despite castrate levels of circulating androgens. This is indicated by continuous expression of...
Edited by: JV
New approach to recurrent prostate cancer may boost survival outcomes
Friday, 19 June 2009- A new study shows that an alpha-particle emitting radiopeptide - radioactive material bound to a synthetic peptide, a component of protein - is effective for treating prostate cancer in mice, according to...
Edited by: ES
US study says gene test predicts prostate cancer
Monday, 8 June 2009- A set of six genes, measured in a blood test, can be used to tell whether a man has prostate cancer, according to a US study.
In a case-control study, the six-gene panel outperformed a standard test --...
Edited by: JV
Brazilian researchers examine early hospital discharge among RRP patients
Thursday, 4 June 2009- Radical Retropubic Prostatectomy (RRP) is one of the most frequent surgery performed by urologists and it has been accompanied by an improvement in surgical results such as duration of...
Edited by: JV
Mature results of a phase 2 study of OGX-011 combined with docetaxel/prednisone vs docetaxel/prednisone in metastatic PCa
Monday, 1 June 2009- Clusterin is a cytoprotective chaperone protein associated with CRPC progression. OGX is a 2&cjs1227;-methoxyethyl antisense that potentiates chemotherapy in xenografts and inhibits clusterin expression at...
Edited by: JV
Women more concerned with PCa recurrence than their men, according to new study
Friday, 29 May 2009- The wives and partners of men with prostate cancer actually worry more about the cancer’s recurrence than the men themselves, according to a study presented at a recent meeting of the Society of Behavioral...
Edited by: ES
Trends in screening for prostate cancer: the French experience
Thursday, 28 May 2008- Screening for prostate cancer (PCa) is still in debate. In France, there is no financial barrier for individuals to be screened with the prostate-specific antigen (PSA) test, and there is no recommendation...
Edited by: JV
